Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon α-2b

European Journal of Gynaecological Oncology

Volumn 31, Issue 5, 2010, Pages 522-529

  Ramos, M C ^a   Mardegan, M C ^a   Peghini, B C ^a   Adad, S J ^a   Michelin, M A ^a   Murta, E F Candido ^b  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^b Federal University of the Triangulo Mineiro UFTM   (Brazil)

Author keywords

2b; Cervical intraepithelial neoplasia; Cervical stroma; CIN 2 3; Cytokines; HPV; Interferon

Indexed keywords

BLAUFERON B; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; RECOMBINANT ALPHA2B INTERFERON; TH1 CYTOKINE; TH2 CYTOKINE; TH3 CYTOKINE; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; FEMALE; HUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; STROMA; TREATMENT FAILURE; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD; WART VIRUS;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOKINES; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON ALFA-2B; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT FAILURE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 78549274018     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Ljubojevic S., Lipozencic J., Grgec D.L., Prstacic R., Skerlev M., Mokos Z.B.: "Human papilloma virus associated with genital infection". Coll. Antropol., 2008, 32, 989.
2. Castellsagué X.: "Natural history and epidemiology of HPV infection and cervical cancer". Gynecol. Oncol., 2008, 110 (suppl. 2), S4.
3. Lehtinen M., Pawlita M., Zumbach K., Lie K., Hakama M., Jellum E. et al.: "Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later". Am. J. Obstet. Gynecol., 2003, 188, 49.
4. Burk R.D., Chen Z., Van Doorslaer K.: "Human papillomaviruses: genetic basis of carcinogenicity". Public Health Genomics, 2009, 12, 281.
5. Stanley M.: "Immune responses to human papillomavirus". Vaccine, 2006, 30 (suppl. 1), S16.
6. Muñoz N., Castellsagué X., de González A.B., Gissmann L. Chapter 1: "HPV in the etiology of human cancer". Vaccine, 2006, 31 (suppl. 3), S3/1.
7. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S.: "Human papillomavirus and cervical cancer". Lancet, 2007, 370, 890.
8. Boulet G., Horvath C., Vanden Broeck D., Sahebali S., Bogers J.: "Human papillomavirus: E6 and E7 oncogenes". Int. J. Biochem. Cell. Biol., 2007, 39, 2006.
9. Syrjänen K.: "New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors". Eur. J. Gynaecol. Oncol., 2008, 29, 205.
10. Ashrafunnessa K.M.: "Cervical intraepithelial neoplasia and its relationship with hormonal contraceptive methods". Bangladesh Med. Res. Counc. Bull., 2008, 34, 33.
11. Da Silva C.S., Adad S.J., Hazarabedian de Souza M.A., Macêdo Barcelos A.C., Sarreta Terra A.P., Murta E.F.: "Increased frequency of bacterial vaginosis and Chlamydia trachomatis in pregnant women with human papillomavirus infection". Gynecol. Obstet. Invest., 2004, 58, 189.
12. Porras C., Rodríguez A.C., Hildesheim A., Herrero R., González P., Wacholder S. et al.: "Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women". Cancer Epidemiol. Biomarkers Prev., 2009, 18, 863.
13. Ferrantini M., Capone I., Belardelli F.: "Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use". Biochimie, 2007, 89, 884.
14. Nomelini R.S., Mardegan M.C., Murta E.F.C.: "Utilization of interferon in gynecologic and breast cancer". Clin. Med. Oncol., 2007, 1, 111.
15. Slotman B.J., Heimerhorst T.J., Wijermans P.W., Calame J.J.: "7Interferon-alpha in treatment of intraepithelial neoplasia of the lower genital tract: a case report". Eur. J. Obstet. Gynecol. Reprod. Biol., 1998, 27, 327.
16. Dunham A.M., McCartney J.C., McCance D.J., Taylor R.W., Dunham A.M., McCartney J.C. et al.: "Effect of perilesional injection of alpha-interferon on cervical intraepithelial neoplasia and associated human papillomavirus infection". J.R. Soc. Med., 1990, 83, 490.
17. Murta E.F.C., Tavares Murta B.M.: "Successful pregnancy after vaginal cancer treated with interferon". Tumori, 2004, 90, 247.
18. Basu P., Biswas J., Mandai R., Choudhury P.: "Is interferon-alpha and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix?". Indian J. Cancer, 2006, 43, 54.
19. Tripathy N.K., Chauhan S.K., Nityanand S.: "Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis". Clin. Exp. Immunol., 2004, 138, 369.
20. Sikorski M., Zrubek H.: "Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection". Eur. J. Gynaecol. Oncol., 2003, 24, 147.
21. Penna C., Fallani M.G., Gordigiani R., Sonni L., Taddei G.L., Marchionni M.: "Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection". Tumori, 1994, 80, 146.
22. Iwasaka T., Hayashi Y., Yokoyama M., Hachisuga T., Sugimori H.: "Interferon gamma treatment for cervical intraepithelial neoplasia". Gynecol. Oncol., 1990, 37, 96.
23. Vanakankovit N., Taneepanichskul S.: "Effect of oral contraceptives on risk of cervical cancer". J. Med. Assoc. Thai, 2008, 91, 7.
24. Bosch F.X., De Sanjosé S.: "The epidemiology of human papillomavirus infection and cervical cancer". Dis. Markers, 2007, 23, 213.
25. Syrjänen K., Shabalova I., Petrovichev N., Kozachenko V., Zakharova T., Pajanidi J. et al.: "Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN". Eur. J. Epidemiol., 2007, 22, 723.
26. Castellsagué X., Munõz N. Chapter 3: "Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking". J. Natl. Cancer Inst. Monogr., 2003, 31, 20.
27. Vetrano G., Lombardi G., Di Leone G., Parisi A., Scardamaglia P., Pate G. et al.: "Cervical intraepithelial neoplasia: risk factors for persistence and recurrence in adolescents". Eur. J. Gynaecol. Oncol., 2007, 28, 189.
28. Tollerud D.J., Clark J.W., Brown L.M., Neuland C.Y., Mann D.L., Pankiw-Trost L.K. et al.: "Association of cigarette smoking with decreased numbers of circulating natural killer cells". Am. Rev. Respir. Dis., 1989, 139, 194.
29. Mehta H., Nazzal K., Sadikot R.T.: "Cigarette smoking and innate immunity". Inflamm. Res., 2008, 57, 497.
30. Runowicz C.D., Lymberis S., Tobias D.: "Cervical Neoplasia and Cigarette Smoking: Are They Linked?". Medscape Womens Health, 1997, 2, 2.
31. El-Sherif A.M., Seth R., Tighe P.J., Jenkins D.: "Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer". J. Pathol., 2001, 195, 179.
32. Song S.H., Lee J.K., Seok O.S., Saw H.S.: "The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix". Gynecol. Oncol., 2007, 104, 732.
33. Mindiola R., Caulejas D., Nuñez-Troconis J., Araujo M., Delgado M., Mosquera J.: "Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix". Invest. Clin., 2008, 49, 533.
34. Song S.H., Lee J.K., Lee N.W., Saw H.S., Kang J.S., Lee K.W.: "Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV)". Gynecol. Oncol., 2008, 108, 543.
35. Scott M., Nakagawa M., Moscicki A.B.: "Cell-mediated immune response to human papillomavirus infection". Clin. Diagn. Lab. Immunol., 2001, 8, 209.
36. Aggarwal B.B.: "Signalling pathways of the TNF superfamily: a double-edged sword". Nat. Rev Immunol., 2003, 3, 745.
37. Glas R., Franksson L., Une C., Eloranta M.L., Ohlén C., Orn A. et al.: "Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses". J. Exp. Med., 2000, 191, 129.
38. Gaiotti D., Chung J., Iglesias M., Nees M., Baker P.D., Evans C.H., Woodworth C.D.: "Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway". Mol. Carcinog., 2000, 27, 97.
39. Tsukui T., Hildesheim A., Schiffman M.H., Lucci J., Contois D., Lawler P. et al.: "Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology". Cancer Res., 1996, 56, 3967.
40. De Gruijl T.D., Bontkes H.J., Van Den Muysenberg A.J., Van Oostveen J.W., Stukart M.J., Verheijen R.H. et al.: "Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix". Eur. J. Cancer, 1999, 35, 490.
41. Peters J.H., Gieseler R., Thiele B., Steinbach F.: "Dendritic cells: from ontogenetic orphans to myelomonocytic descendants". Immunol. Today, 1996, 17, 273.
42. Pardo-Govea T., Callejas D., Núnez Troconis J., Araujo M., Costa L., Pons H. et al.: "Gamma interferon (IFN-gamma), tumor necrosis factor alpha (TNF-alpha) and interleukins 2,4 and 6 (IL-2, IL-4, IL-6) in cervical-uterine cells of intraepithelial neoplasia: a preliminary report". Invest. Clin., 2005, 46, 5.
43. Gonçalvez M.A., Donadi E.A.: "Immune cellular response to HPV: current concepts"7. Braz. J. Infect. Dis., 2004, 8, 1.
44. Clerici M., Merola M., Ferrario E., Trabattoni D., Villa M.L., Stefanon B. et al.: "Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection". J. Natl. Cancer Inst., 1997, 89, 245.
45. Bais A.G., Beckmann I., Lindemansj Ewing P.C., Meijer C.J., Snijders P.J., Heimerhorst T.J.: "A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions". J. Clin. Pathol., 2005, 58, 1096.
46. Lembo D., Donalisio M., De Andrea M., Cornaglia M., Scutera S., Musso T. et al.: "A cell-based high-throughput assay for screening inhibitors of human papillomavirus-16 long control region activity". FASEB J., 2006, 20, 148.
47. Scott M.E., MA Y., Kuzmich L., Moscicki A.B.: "Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3". Int. J. Cancer, 2009, 124, 1379.
48. Farzaneh F., Roberts S., Mandai D., Ollier B., Winters U., Kitchener H.C. et al.: "The IL-10 -1082G polymorphism is associated with clearance of HPV infection". BJOG, 2006, 113, 961.
49. Zoodsma M., Nolle I.M., Schipper M., Oosterom E., Van Der Steege G., De Vries E.G. et al.: "Interleukin-10 and Pas polymorphism and susceptibility for (pre) neoplastic cervical disease". Int. J. Gynecol. Cancer, 2005, 15 (suppl. 3), 282.
50. Wilczynski J.R., Radwan M., Kalinka J.: "The characterization and role of regulatory T cells in immune reactions". Front. Biosci, 2008, 1, 2266.
51. El-Sherif A.M., Seth R., Tighe P.J., Jenkins D.: "Decreased synthesis and expression of TGF-beta1, beta2, and beta3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, and immunocytochemistry". J. Pathol., 2000, 192, 494.
52. Tervahauta A., Syrjänen S., Yliskoski M., Gold L.I., Syrjänen K.: "Expression of transforming growth factor-beta 1 and -beta 2 in human papillomavirus (HPV)-associated lesions of the uterine cervix". Gynecol. Oncol., 1994, 54, 349.
53. Soufla G., Sifakis S., Baritaki S., Zafiropoulos A., Koumantakis E., Spandidos D.A.: "VEGR FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix". Cancer Lett., 2005, 221, 105.
54. Braun L., Dürst M., Mikumo R., Crowley A., Robinson M.: "Regulation of growth and gene expression in human papillomavirus- transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection". Mol. Carcinog., 1992, 6, 100.
55. Woodman C.B., Collins S.I., Young L.S.: "The natural history of cervical HPV infection: unresolved issues". Nat. Rev. Cancer, 2007, 7, 11.
56. Xi L.F., Kiviat N.B., Galloway D.A., Zhou X.H., Ho J., Koutsky L.A.: "Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3". J. Infect. Dis., 2008, 198, 324.